Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTAW) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to $0.7.

  • Strata Critical Medical's EPS (Weighted Average and Diluted) rose 110000.0% to $0.7 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.49, marking a year-over-year increase of 16621.62%. This contributed to the annual value of -$0.35 for FY2024, which is 5363.8% up from last year.
  • According to the latest figures from Q3 2025, Strata Critical Medical's EPS (Weighted Average and Diluted) is $0.7, which was up 110000.0% from -$0.05 recorded in Q2 2025.
  • Strata Critical Medical's 5-year EPS (Weighted Average and Diluted) high stood at $0.7 for Q3 2025, and its period low was -$0.47 during Q2 2021.
  • In the last 5 years, Strata Critical Medical's EPS (Weighted Average and Diluted) had a median value of -$0.14 in 2023 and averaged -$0.1.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 529076.41% in 2021, then soared by 110000.0% in 2025.
  • Strata Critical Medical's EPS (Weighted Average and Diluted) (Quarter) stood at $0.01 in 2021, then crashed by 2263.87% to -$0.22 in 2022, then plummeted by 112.58% to -$0.46 in 2023, then soared by 47.89% to -$0.24 in 2024, then soared by 392.04% to $0.7 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.7 in Q3 2025, compared to -$0.05 in Q2 2025 and -$0.04 in Q1 2025.